НовостиBenzingaBarclays Maintains Overweight on BeOne Medicines, Raises Price Target to $446 Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $446 Benzinga 2026.11.06 16:04 (GMT+0) Открыть на Benzinga Другие новости